Conference Call with NGL Fine - Chem Management and Analysts on Q4FY24 Performance and Outlook. Listen to the full earnings transcript.
Conference Call with NGL Fine - Chem Management and Analysts on Q2FY24 Performance and Outlook. Listen to the full earnings transcript.
Pharmaceuticals firm NGL Fine-Chem declares Q3FY22 result: Revenue growth of 12% YoY in Q3FY22 and 28% YoY in 9MFY22, driven by strong volume growth and increasing market penetration Continuing rise in input prices (27% YoY in Q3), fuel costs (167% YoY in Q3) and freight costs (43% YoY in Q3) led to margin and profitability contraction during the quarter Increased inventories to cater to growing demand, while maintaining a strong working capital with a NWC of 78 days as of Sep’21 Incurred CAPEX of ~ Rs 17 crores for H1FY22 Continue to remain Net Cash positive at Rs 16 crores as of Sep’21 Result PDF
Highlights: Witnessed continuing strong demand with revenue growth of 15% YoY in Q2FY22 and 39% YoY in H1FY22; holding onto market share gains in key products. Rise in input prices, power & fuel costs and freight costs led to margin and profitability contraction during the quarter Normalization of business expense post covid such as travel, sales, marketing, etc., also had an impact on margins Increased inventories to cater to growing demand, while maintaining a strong working capital with a NWC of 78 days as of Sep’21 Incurred CAPEX of ~ Rs 17 crores for H1FY22 Continue to remain Net Cash positive at Rs 16 crores as of Sep’21 Result PDF